Depletion of specific cellular proteins is a powerful tool in biological research and has many medical and agricultural benefits. 
The selective depletion of intracellular proteins is a powerful approach for dissecting cellular processes and recently has been exploited in a number of medical and agricultural applications (1) . Most techniques involve direct or indirect manipulation of the targeted gene or its expression and include such commonly used methods as gene disruption, suppression with antisense RNA, and gene silencing (1, 2) . In only a few cases have proteolytic methods for removing the protein product been exploited, even though. this catabolic step can be rapid and occurs with high specificity (3, 4) . In one example, the attachment of destabilizing peptide domains proved effective but is inherently unsuitable for removing endogenous unmodified targets (4) .
We present here a conceptually new proteolytic approach for reducing the levels of specific eukaryotic proteins by redirecting the ubiquitin-dependent proteolytic pathway to recognize and break down otherwise stable proteins. In the pathway, ubiquitin functions as a reusable signal for proteolysis (5, 6) . Via an ATP-dependent cascade of reactions, proteins targeted for degradation are first covalently tagged with chains of multiple ubiquitins; the resulting ubiquitin-protein conjugates then are selectively recognized by the ATP-dependent 26S proteasome, which degrades the target protein and releases ubiquitin intact. The pathway is responsible for degrading most abnormal proteins and many short-lived cell regulators (5, 6) .
Within the pathway, E2s (ubiquitin-conjugating enzymes)
play a prominent role in selectivity by helping recognize appropriate targets for ubiquitination (5) (6) (7) (9) , rabbit reticulocyte lysate (10) , and crude membrane preparations of A431 epidermoid carcinoma cells (11) were prepared as described. Reduced carboxymethylated 125I-labeled IgGs (125I-IgGs) were synthesized as described (12) using lodo-Beads (Pierce) to 125I-label mouse IgGs (Sigma) and iodoacetamide for alkylation.
Construction of Chimeric E2s. All manipulations were performed with theAtUBCl and TaUBC4 genes inserted in the pET3a expression vector (8) . Xho I sites were engineered by site-directed mutagenesis into the 3' ends of pET-AtUBC1 and pET-TaUBC4 with the oligonucleotides GCAAAGCTGGA-CTGCTCTCGAGTAGTAGTTTGTTGTAAGCG and GG- (15) ] was amplified with oligonucleotides CTTAATGACCTCGAGGCTCCAAA-AGCTGATGCGCAAC and GCTTGTTATTCTCGAGTTA-TTTTGGTGCTT designed so thatXho I sites were added to the 5' and the 3' ends of the amplified fragment and a stop codon followed the 327 codon. pET-AtUBC1-spacer-protein ADABC was constructed by ligating this fragment into pET-AtUBC1-spacer digested with Xho I. pET-AtUBC1-spacer-Spep was constructed using PCR to amplify the 15-aa S-peptide fragment (16) from pET-29c (Novagen) with the oligonucleotides GATCTCG-AGATGAAAGAAACCGCTGC and CCCGGATCCTAGCT-GTCCATGTGC. The resulting fragment was digested with Xho I/BamHI and ligated into pET-AtUBC1-spacer similarly digested. pET-AtUBC1-spacer-Sant was created by ligating the annealed oligonucleotides TCGACTACAACTTCGAAGTTC-TGTGAG and GATCCTCACAGAACTTCGAAGTTGTAG into pET-AtUBC1-spacer digested with Xho I/BamHI. Production and Assay of Chimeric E2s. E2 proteins were synthesized in Escherichia coli as described (8) . For protein degradation assays, E2s were partially purified by DE-52 chromatography using a step elution of 100 mM KCI in 50 mM Tris HCl, pH 7.2 (4°C)/1 mM dithiothreitol (DTT). Thiol ester and conjugation assays were performed as described (8), except that thiol ester reactions proceeded for 5 min at room temperature and the conjugation reaction mixtures were incubated for 2 h at 30°C. The amount of E2 protein used in each conjugation reaction was normalized so that equivalent thiol ester-forming activities were used. Where indicated, conjugation products of IgGs were partially purified by precipitation with protein A-agarose beads (Sigma).
UBC4
PROTEIN A Importantly, addition of the protein AD domain to TaUBC4 increased substantially the ubiquitination of IgGs (Fig. 1 B and  C) . In conjugation reaction mixtures containing the chimeric E2, 1251-ubiquitin, El, and ATP, the heavy chain of both rabbit and mouse IgGs became modified, with a monoubiquitinated species being the predominant product. Conjugation was specific for certain classes of IgGs and reflected the binding specificity of intact protein A (Fig. 1C) . Ubiquitination was not evident for goat IgGs but was substantial for both rabbit and mouse IgGs in accord with the poor affinity of protein A for goat IgGs and the high affinity of protein A for the rabbit and mouse counterparts (17) .
Other types of antibody-antigen interactions were also successful in modifying E2 specificity. For example, unmodified TaUBC4 would effectively conjugate ubiquitin to the heavy chains of polyclonal immunoglobulins that bind TaUBC4 (data not shown). Likewise, TaUBC4 containing the 10-aa c-Myc epitope [EQKLISEEDL (13) ] fused directly to its C terminus would conjugate ubiquitin to the heavy chain of the corresponding 9E10 IgG (13) Recognition of the anti-c-Myc IgG 9E10 was not restricted to TaUBC4-c-myc but also was possible with AtUBC1 provided a short spacer (PPVDAAAAAL), designed to extend from the E2 core, was inserted between the E2 and c-Myc epitope. When AtUBC1-spacer-c-myc was added to conjugation reaction mixtures containing 9E10 IgG, monoubiquitination of the IgG heavy chain was detected (Fig. 2 Right) . This adduct was absent when unmodified AtUBC1 or the spacerless AtUBC1-c-myc was used or when excess c-Myc peptide was added to reaction mixtures containing AtUBC1-spacer-cmyc.
Other protein-protein interactions were examined in addition to those using IgGs. In one example, the 49-aa peptide hormone, TGF-a and its binding partner epidermal growth factor receptor (EGFR) were exploited (18) . When a TaUBC4-TGF-a fusion was added to crude membrane preparations from human epidermal cells (14) along with 125I1 ubiquitin, ATP, and El, specific monoubiquitination of the EGFR was detected (Fig. 3) . The product was not detected in the absence of added E2s, when an equal amount of unmodified TaUBC4 was used, or when an excess of a TGF-a homolog EGF (18) was added as a competitor (Fig. 4) . These results highlight the specificity and sensitivity of the E2-protein interaction; even though we were unable to detect EGFR among the multitude of other proteins in the membrane preparations by protein staining (data not shown), it was easily detected by 1251-ubiquitin tagging.
As another example, we used the S-protein and S-peptide binding pair of RNase A (16). A 15-aa peptide containing the essential binding elements of S peptide (16) was appended to the C terminus of AtUBC1 through the spacer described above (see Fig. 3 ). The chimera, AtUBC1-spacer-Spep, was effective in binding 1251-ubiquitin via a thiol ester bond and, when added to conjugation reaction mixtures, specifically ubiquitinated free S protein (Fig. 5 ). Conjugates were not detected when Engineering an E2 to recognize and conjugate ubiquitin to RNase A S protein by exploiting as ligands either the S peptide or an antagonist peptide identified from a phage-display library (16) . AtUBC1 was modified to contain either a 15-aa fragment of the S peptide (UBC1-spacer-Spep) or the S-peptide antagonist YNFEVL (UBC1-spacer-Sant) linked to the C terminus through a 10-aa spacer. (A) Activities of AtUBC1, AtUBC1-spacer-Spep, and AtUBC1-spacer-Sant were determined by thiol ester assay using 1251-ubiquitin. (B) 1251-ubiquitin conjugation reactions using the AtUBC1 derivatives and S protein as the target. Reactions were performed with equal amounts of active E2 (determined by thiol ester assay) and S protein at 200 ,ug/ml. Products were subjected to SDS/PAGE and autoradiography. Where indicated, conjugation reaction mixtures contained free S peptide (1 mg/ml).
unmodified AtUBC1 was used instead or when free S peptide was added in excess.
For the chimeric E2s to generate substrates suitable for breakdown by the 26S proteasome, multiubiquitination of the target may be essential (5, 6) . However, in all our examples, monoubiquitinated targets were the predominant products. We found that multiubiquitination will occur, provided additional cellular factors are included in the conjugation reaction mixtures. Although mouse IgG heavy chains were only monoubiquitinated by TaUBC4-protein AD alone, they were conjugated with multiple ubiquitins when either wheat germ extract or rabbit reticulocyte lysate was included in the reaction mixture (Fig. 1D) . Both of these crude preparations represent rich sources of enzymes involved in ubiquitin conjugation (5, 9) . In each case, a ladder of ubiquitin-IgG heavy chain conjugates was detected with size distributions similar to those found with natural ubiquitin pathway substrates (19) (20) (21) .
Success of this approach will require that the ubiquitinated proteins serve as substrates for degradation by the 26S proteasome (5, 10 (15) attached to the C terminus of E2 through a 10-aa spacer. The ability of AtUBC1 and AtUBC1-spacer-protein ADABC to conjugate ubiquitin to reduced carboxymethylated mouse 1251-IgG was examined in both the absence (A) and the presence (B) of rabbit reticulocyte lysate. Conjugation reactions were performed in the presence of ATP, nonlabeled ubiquitin, and equal amounts of E2, as determined by thiol ester assay. At the times indicated, the reaction mixtures were quenched and the products were subjected to SDS/ PAGE and autoradiography. Designations indicate positions of AtUBC1 was fused with a 238-aa peptide encompassing all four immunoglobulin-binding domains of protein A [domains DABC (15) ] through the 10-aa spacer PPVDAAAAAL (AtUBC1-spacer-protein ADABC). Because E. coli extracts contain an inhibitor of the 26S proteasome (data not shown), we partially purified the E2s before addition to the degradation assay. When incubated with reduced carboxymethylated 125I-IgGs (12), nonradioactive ubiquitin, El, and ATP, AtUBC1-spacer-protein ADABC ubiquitinated a substantial percentage of the IgG heavy chain; within 90 min as much as 50% of the IgG heavy chains was modified (Fig. SA) . While prior reactions using nonradioactive unmodified IgG produced monoubiquitinated products (Fig. 1 B and C) , multiubiquitinated products were evident with the modified 125I-IgGs, even in the absence of extra factors. Conversely, no ubiquitinated products were observed when unmodified AtUBC1 was used (Fig. SA) .
Addition of reticulocyte lysate, a rich source of active 26S proteasome (5, 10) , to the conjugation reaction mixtures containing 125I-IgG enhanced the multiubiquitination of the IgG heavy chain (compare Fig. 5 B and C) . Importantly, inclusion of the 26S proteasome also led to ATP-dependent breakdown of the 125I-IgGs (Fig. SC) . Degradation was observed only in those reaction mixtures containing AtUBC1-spacer-protein ADABC and required ATP, in accordance with the ATP dependence of the 26S proteasome (5) . After a 4-h incubation at 37°C, -12% of the 125I was found in a trichloroacetic acid-soluble fraction containing small peptides and free amino acids. The percentage of 125I-IgG degraded in an ATP-dependent manner was comparable to that observed with 125I-lysozyme (data not shown), a common substrate for ubiquitin-dependent proteolysis in reticulocyte lysates (10), suggesting that the limited amount of 125I-IgG ultimately degraded reflected the in vitro conditions used.
Although the targeted proteolysis approach requires an interacting peptide to recognize the target protein, it need not be limited to those proteins having natural binding partners. We found that an artificial ligand, YNFEVL, identified from a phage display library as a binding antagonist of the S peptide to the RNase A S protein (16), was as effective as S peptide in directing the ubiquitination of S protein. AtUBC1 containing this hexapeptide attached via the spacer to the C terminus (AtUBC-spacer-Sant) was as active in thiol ester assays and in conjugating ubiquitin to S protein as AtUBC1-spacer-Spep (Fig. 4) .
Taken together, these results show conceptually that the ubiquitin proteolytic pathway can be engineered to enhance the removal of selected proteins simply by appending appropriate interacting domains onto the C termini of E2s. These binding affinities allow E2s to recognize and ubiquitinate their corresponding binding partners and can ultimately lead to ATP-dependent degradation of the partners in vitro. Here we tested a variety of ligand-protein interactions, including protein A-antibody, epitope-antibody, peptide hormonereceptor, and protein subdomains. The ligands ranged in size from 6 to 238 aa and were either natural or artificial. In most cases, appending peptide ligands onto the E2s did little to affect the ubiquitin-accepting activity of the E2, suggesting that there are few constraints on the types of binding interactions that can be exploited. We did find that a spacer peptide [either natural as in TaUBC4 (8) or artificial] separating the E2 core from the ligand may be needed, presumably to facilitate access of the E2 to available accessible lysines within the target. It is noteworthy that all of the substrates we tested became targets of ubiquitination even though they are naturally unaffected by the ubiquitin pathway because of their extracytoplasmic location or prokaryotic origin (14) (15) (16) . This implies that the only limitations to target choice may be the need for an available lysine(s) and its accessibility to the ubiquitin pathway (5) (6) (7) .
Given the high conservation of the ubiquitin-dependent proteolytic pathway in all eukaryotes examined (5-7), this targeted proteolytic approach should be applicable in animals, plants, and fungi with E2s derived from various sources. Although our studies employed in vitro systems for ubiquitin conjugation and proteolysis, it is likely that the system will function in vivo given that the cell-free systems used here were similar to those previously used to successfully reconstitute in vivo ubiquitination and degradation (5, 9, 10) . If successful in vivo, the approach may have several advantages over other methods to eliminate proteins, including its catalytic nature, the fact that neither the target protein nor its corresponding gene requires modification, and its theoretical ability to target for degradation proteins not encoded by the host cell. Predefined ubiquitination may also have potential uses in the biochemical identification of protein-binding partners. As exemplified with EGFR, E2s engineered with appropriate ligands could be used to identify and purify unknown binding partners from a complex mixture by specific labeling with appropriately modified ubiquitin.
